Health care costs associated with hepatocellular carcinoma: A population-based study

Hla Hla Thein, Wanrudee Isaranuwatchai, Michael A. Campitelli, Jordan J. Feld, Eric Yoshida, Morris Sherman, Jeffrey S Hoch, Stuart Peacock, Murray D. Krahn, Craig C. Earle

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

Although the burden of hepatocellular carcinoma (HCC) is an escalating public health problem, it has not been rigorously estimated within a Canadian context. We conducted a population-based study using Ontario Cancer Registry linked administrative data. The mean net costs of care due to HCC were estimated using a phase of care approach and generalized estimating equations. Using an incidence approach, the mean net costs of care were applied to survival probabilities of HCC patients to estimate 5-year net costs of care and extrapolated to the Canadian population of newly diagnosed HCC patients in 2009. During 2002-2008, 2,341 HCC cases were identified in Ontario. The mean (95% confidence interval [CI]) net costs of HCC care per 30 patient-days (2010 US dollars) were $3,204 ($2,863-$3,545) in the initial phase, $2,055 ($1,734-$2,375) in the continuing care phase, and $7,776 ($5,889-$9,663) in the terminal phase. The mean (95% CI) 5-year net cost of care was $77,509 ($60,410-$94,607) and the 5-year aggregate net cost of care was $106 million ($83-$130 million) (undiscounted). The net costs of patients receiving liver transplantation only and those undergoing surgical resection only were highest in the terminal phase. The net cost of patients receiving radiofrequency ablation as the only treatment was relatively low in the initial phase, and there were no significant differences in the continuing and terminal phases. Conclusion: Our findings suggest that costs attributable to HCC are significant in Canada and expected to increase. Our findings of phase-specific cost estimates by resource categories and type of treatment provide information for future cost-effectiveness analysis of potential innovative interventions, resource allocation, and health care budgeting, and public health policy to improve the health of the population.

Original languageEnglish (US)
Pages (from-to)1375-1384
Number of pages10
JournalHepatology
Volume58
Issue number4
DOIs
StatePublished - Oct 2013
Externally publishedYes

Fingerprint

Health Care Costs
Hepatocellular Carcinoma
Costs and Cost Analysis
Population
Ontario
Public Health
Confidence Intervals
Resource Allocation
Public Policy
Health Policy
Liver Transplantation
Cost-Benefit Analysis
Canada
Registries
Delivery of Health Care
Survival
Incidence
Health
Therapeutics

ASJC Scopus subject areas

  • Hepatology

Cite this

Thein, H. H., Isaranuwatchai, W., Campitelli, M. A., Feld, J. J., Yoshida, E., Sherman, M., ... Earle, C. C. (2013). Health care costs associated with hepatocellular carcinoma: A population-based study. Hepatology, 58(4), 1375-1384. https://doi.org/10.1002/hep.26231

Health care costs associated with hepatocellular carcinoma : A population-based study. / Thein, Hla Hla; Isaranuwatchai, Wanrudee; Campitelli, Michael A.; Feld, Jordan J.; Yoshida, Eric; Sherman, Morris; Hoch, Jeffrey S; Peacock, Stuart; Krahn, Murray D.; Earle, Craig C.

In: Hepatology, Vol. 58, No. 4, 10.2013, p. 1375-1384.

Research output: Contribution to journalArticle

Thein, HH, Isaranuwatchai, W, Campitelli, MA, Feld, JJ, Yoshida, E, Sherman, M, Hoch, JS, Peacock, S, Krahn, MD & Earle, CC 2013, 'Health care costs associated with hepatocellular carcinoma: A population-based study', Hepatology, vol. 58, no. 4, pp. 1375-1384. https://doi.org/10.1002/hep.26231
Thein HH, Isaranuwatchai W, Campitelli MA, Feld JJ, Yoshida E, Sherman M et al. Health care costs associated with hepatocellular carcinoma: A population-based study. Hepatology. 2013 Oct;58(4):1375-1384. https://doi.org/10.1002/hep.26231
Thein, Hla Hla ; Isaranuwatchai, Wanrudee ; Campitelli, Michael A. ; Feld, Jordan J. ; Yoshida, Eric ; Sherman, Morris ; Hoch, Jeffrey S ; Peacock, Stuart ; Krahn, Murray D. ; Earle, Craig C. / Health care costs associated with hepatocellular carcinoma : A population-based study. In: Hepatology. 2013 ; Vol. 58, No. 4. pp. 1375-1384.
@article{3df4f6e3b2b146e882595e0b4fde4e62,
title = "Health care costs associated with hepatocellular carcinoma: A population-based study",
abstract = "Although the burden of hepatocellular carcinoma (HCC) is an escalating public health problem, it has not been rigorously estimated within a Canadian context. We conducted a population-based study using Ontario Cancer Registry linked administrative data. The mean net costs of care due to HCC were estimated using a phase of care approach and generalized estimating equations. Using an incidence approach, the mean net costs of care were applied to survival probabilities of HCC patients to estimate 5-year net costs of care and extrapolated to the Canadian population of newly diagnosed HCC patients in 2009. During 2002-2008, 2,341 HCC cases were identified in Ontario. The mean (95{\%} confidence interval [CI]) net costs of HCC care per 30 patient-days (2010 US dollars) were $3,204 ($2,863-$3,545) in the initial phase, $2,055 ($1,734-$2,375) in the continuing care phase, and $7,776 ($5,889-$9,663) in the terminal phase. The mean (95{\%} CI) 5-year net cost of care was $77,509 ($60,410-$94,607) and the 5-year aggregate net cost of care was $106 million ($83-$130 million) (undiscounted). The net costs of patients receiving liver transplantation only and those undergoing surgical resection only were highest in the terminal phase. The net cost of patients receiving radiofrequency ablation as the only treatment was relatively low in the initial phase, and there were no significant differences in the continuing and terminal phases. Conclusion: Our findings suggest that costs attributable to HCC are significant in Canada and expected to increase. Our findings of phase-specific cost estimates by resource categories and type of treatment provide information for future cost-effectiveness analysis of potential innovative interventions, resource allocation, and health care budgeting, and public health policy to improve the health of the population.",
author = "Thein, {Hla Hla} and Wanrudee Isaranuwatchai and Campitelli, {Michael A.} and Feld, {Jordan J.} and Eric Yoshida and Morris Sherman and Hoch, {Jeffrey S} and Stuart Peacock and Krahn, {Murray D.} and Earle, {Craig C.}",
year = "2013",
month = "10",
doi = "10.1002/hep.26231",
language = "English (US)",
volume = "58",
pages = "1375--1384",
journal = "Hepatology",
issn = "0270-9139",
publisher = "John Wiley and Sons Ltd",
number = "4",

}

TY - JOUR

T1 - Health care costs associated with hepatocellular carcinoma

T2 - A population-based study

AU - Thein, Hla Hla

AU - Isaranuwatchai, Wanrudee

AU - Campitelli, Michael A.

AU - Feld, Jordan J.

AU - Yoshida, Eric

AU - Sherman, Morris

AU - Hoch, Jeffrey S

AU - Peacock, Stuart

AU - Krahn, Murray D.

AU - Earle, Craig C.

PY - 2013/10

Y1 - 2013/10

N2 - Although the burden of hepatocellular carcinoma (HCC) is an escalating public health problem, it has not been rigorously estimated within a Canadian context. We conducted a population-based study using Ontario Cancer Registry linked administrative data. The mean net costs of care due to HCC were estimated using a phase of care approach and generalized estimating equations. Using an incidence approach, the mean net costs of care were applied to survival probabilities of HCC patients to estimate 5-year net costs of care and extrapolated to the Canadian population of newly diagnosed HCC patients in 2009. During 2002-2008, 2,341 HCC cases were identified in Ontario. The mean (95% confidence interval [CI]) net costs of HCC care per 30 patient-days (2010 US dollars) were $3,204 ($2,863-$3,545) in the initial phase, $2,055 ($1,734-$2,375) in the continuing care phase, and $7,776 ($5,889-$9,663) in the terminal phase. The mean (95% CI) 5-year net cost of care was $77,509 ($60,410-$94,607) and the 5-year aggregate net cost of care was $106 million ($83-$130 million) (undiscounted). The net costs of patients receiving liver transplantation only and those undergoing surgical resection only were highest in the terminal phase. The net cost of patients receiving radiofrequency ablation as the only treatment was relatively low in the initial phase, and there were no significant differences in the continuing and terminal phases. Conclusion: Our findings suggest that costs attributable to HCC are significant in Canada and expected to increase. Our findings of phase-specific cost estimates by resource categories and type of treatment provide information for future cost-effectiveness analysis of potential innovative interventions, resource allocation, and health care budgeting, and public health policy to improve the health of the population.

AB - Although the burden of hepatocellular carcinoma (HCC) is an escalating public health problem, it has not been rigorously estimated within a Canadian context. We conducted a population-based study using Ontario Cancer Registry linked administrative data. The mean net costs of care due to HCC were estimated using a phase of care approach and generalized estimating equations. Using an incidence approach, the mean net costs of care were applied to survival probabilities of HCC patients to estimate 5-year net costs of care and extrapolated to the Canadian population of newly diagnosed HCC patients in 2009. During 2002-2008, 2,341 HCC cases were identified in Ontario. The mean (95% confidence interval [CI]) net costs of HCC care per 30 patient-days (2010 US dollars) were $3,204 ($2,863-$3,545) in the initial phase, $2,055 ($1,734-$2,375) in the continuing care phase, and $7,776 ($5,889-$9,663) in the terminal phase. The mean (95% CI) 5-year net cost of care was $77,509 ($60,410-$94,607) and the 5-year aggregate net cost of care was $106 million ($83-$130 million) (undiscounted). The net costs of patients receiving liver transplantation only and those undergoing surgical resection only were highest in the terminal phase. The net cost of patients receiving radiofrequency ablation as the only treatment was relatively low in the initial phase, and there were no significant differences in the continuing and terminal phases. Conclusion: Our findings suggest that costs attributable to HCC are significant in Canada and expected to increase. Our findings of phase-specific cost estimates by resource categories and type of treatment provide information for future cost-effectiveness analysis of potential innovative interventions, resource allocation, and health care budgeting, and public health policy to improve the health of the population.

UR - http://www.scopus.com/inward/record.url?scp=84884977723&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84884977723&partnerID=8YFLogxK

U2 - 10.1002/hep.26231

DO - 10.1002/hep.26231

M3 - Article

C2 - 23300063

AN - SCOPUS:84884977723

VL - 58

SP - 1375

EP - 1384

JO - Hepatology

JF - Hepatology

SN - 0270-9139

IS - 4

ER -